
Danaher Corp.
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District Of Columbia.
Stock Performance (90 Days)
Layoff History
Earnings Call Transcripts
View All →Danaher reported Q3 2025 revenue of $6.1B, up 4.5% YoY, with 3.0% core growth. Adjusted diluted EPS reached $1.89, beating expectations. Full-year adjusted EPS guidance of $7.70-$7.80 was maintained.
The provided document is an 8-K filing referencing a Q2 2025 press release and does not contain the Q3 2025 earnings call transcript or financial results for DANAHER CORP /DE/ (DHR).
Danaher reported solid Q1 2025 results, with revenues increasing 2.0% to $5.8 billion and core revenue up 2.5%. Diluted EPS grew 2.5% to $1.48, while adjusted diluted EPS saw a robust 5.5% increase, demonstrating strong execution in a dynamic environment.
Recent News
Other Diagnostics & Research Companies
View All →Frequently Asked Questions
Has DANAHER CORP /DE/ had layoffs?
How many employees does DANAHER CORP /DE/ have?
What industry is DANAHER CORP /DE/ in?
Is DANAHER CORP /DE/ a publicly traded company?
Where is DANAHER CORP /DE/ headquartered?
Disclaimer
Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.
This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.
Found an error? Report it here.